---
document_datetime: 2025-11-23 08:04:17
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/leflunomide-teva.html
document_name: leflunomide-teva.html
version: success
processing_time: 0.125173
conversion_datetime: 2025-12-28 13:39:22.755609
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Leflunomide Teva

[RSS](/en/individual-human-medicine.xml/66857)

##### Lapsed

This medicine's authorisation has lapsed

leflunomide

Medicine

Human

Lapsed

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Leflunomide Teva](#more-information-on-leflunomide-teva-1455)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 10 March 2014, the marketing authorisation of Leflunomide Teva ceased to be valid in the European Union (EU). The cessation of validity is due to the fact that the marketing authorisation holder, Teva Pharma B.V., had not marketed Leflunomide Teva in the EU since its initial marketing authorisation in March 2011.

In accordance with provisions of the sunset clause1 , the marketing authorisation of the medicinal product lapsed as the product had not been marketed in any of the EU Member States within three years of its initial authorisation. Leflunomide Teva was granted marketing authorisation in the EU on 10 March 2011 for the treatment of adult patients with active rheumatoid arthritis. The marketing authorisation was initially valid for a 5-year period.

Leflunomide Teva is a generic medicine of Arava which is authorised in the EU to treat adult patients with active rheumatoid arthritis and active psoriatic arthritis. Leflunomide Teva was a duplicate application to Repso, which is marketed in the EU. The marketing authorisation holder will maintain the marketing authorisation for Repso.

The European Public Assessment Report (EPAR) for Leflunomide Teva is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

Leflunomide Teva : EPAR - Summary for the public

English (EN) (193.3 KB - PDF)

**First published:** 21/03/2011

**Last updated:** 18/03/2014

[View](/en/documents/overview/leflunomide-teva-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-71)

български (BG) (318.85 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/bg/documents/overview/leflunomide-teva-epar-summary-public_bg.pdf)

español (ES) (259.43 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/es/documents/overview/leflunomide-teva-epar-summary-public_es.pdf)

čeština (CS) (296.37 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/cs/documents/overview/leflunomide-teva-epar-summary-public_cs.pdf)

dansk (DA) (195.42 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/da/documents/overview/leflunomide-teva-epar-summary-public_da.pdf)

Deutsch (DE) (259.61 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/de/documents/overview/leflunomide-teva-epar-summary-public_de.pdf)

eesti keel (ET) (193.65 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/et/documents/overview/leflunomide-teva-epar-summary-public_et.pdf)

ελληνικά (EL) (264.83 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/el/documents/overview/leflunomide-teva-epar-summary-public_el.pdf)

français (FR) (522.83 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/fr/documents/overview/leflunomide-teva-epar-summary-public_fr.pdf)

italiano (IT) (258.23 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/it/documents/overview/leflunomide-teva-epar-summary-public_it.pdf)

latviešu valoda (LV) (241.96 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/lv/documents/overview/leflunomide-teva-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (222.41 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/lt/documents/overview/leflunomide-teva-epar-summary-public_lt.pdf)

magyar (HU) (291.45 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/hu/documents/overview/leflunomide-teva-epar-summary-public_hu.pdf)

Malti (MT) (296.86 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/mt/documents/overview/leflunomide-teva-epar-summary-public_mt.pdf)

Nederlands (NL) (257.41 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/nl/documents/overview/leflunomide-teva-epar-summary-public_nl.pdf)

polski (PL) (235.33 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/pl/documents/overview/leflunomide-teva-epar-summary-public_pl.pdf)

português (PT) (256.05 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/pt/documents/overview/leflunomide-teva-epar-summary-public_pt.pdf)

română (RO) (283.68 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/ro/documents/overview/leflunomide-teva-epar-summary-public_ro.pdf)

slovenčina (SK) (294.29 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/sk/documents/overview/leflunomide-teva-epar-summary-public_sk.pdf)

slovenščina (SL) (229.59 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/sl/documents/overview/leflunomide-teva-epar-summary-public_sl.pdf)

Suomi (FI) (257.62 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/fi/documents/overview/leflunomide-teva-epar-summary-public_fi.pdf)

svenska (SV) (271.75 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/sv/documents/overview/leflunomide-teva-epar-summary-public_sv.pdf)

## Product information

Leflunomide Teva : EPAR - Product Information

English (EN) (879.05 KB - PDF)

**First published:** 21/03/2011

**Last updated:** 18/03/2014

[View](/en/documents/product-information/leflunomide-teva-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-888)

български (BG) (1.79 MB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/bg/documents/product-information/leflunomide-teva-epar-product-information_bg.pdf)

español (ES) (900.41 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/es/documents/product-information/leflunomide-teva-epar-product-information_es.pdf)

čeština (CS) (1.42 MB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/cs/documents/product-information/leflunomide-teva-epar-product-information_cs.pdf)

dansk (DA) (932.66 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/da/documents/product-information/leflunomide-teva-epar-product-information_da.pdf)

Deutsch (DE) (914.22 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/de/documents/product-information/leflunomide-teva-epar-product-information_de.pdf)

eesti keel (ET) (860.04 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/et/documents/product-information/leflunomide-teva-epar-product-information_et.pdf)

ελληνικά (EL) (1.82 MB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/el/documents/product-information/leflunomide-teva-epar-product-information_el.pdf)

français (FR) (947.19 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/fr/documents/product-information/leflunomide-teva-epar-product-information_fr.pdf)

hrvatski (HR) (1023.47 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/hr/documents/product-information/leflunomide-teva-epar-product-information_hr.pdf)

íslenska (IS) (877.7 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/is/documents/product-information/leflunomide-teva-epar-product-information_is.pdf)

italiano (IT) (958.68 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/it/documents/product-information/leflunomide-teva-epar-product-information_it.pdf)

latviešu valoda (LV) (1.53 MB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/lv/documents/product-information/leflunomide-teva-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1000.67 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/lt/documents/product-information/leflunomide-teva-epar-product-information_lt.pdf)

magyar (HU) (1.36 MB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/hu/documents/product-information/leflunomide-teva-epar-product-information_hu.pdf)

Malti (MT) (1.52 MB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/mt/documents/product-information/leflunomide-teva-epar-product-information_mt.pdf)

Nederlands (NL) (887.78 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/nl/documents/product-information/leflunomide-teva-epar-product-information_nl.pdf)

norsk (NO) (887.93 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/no/documents/product-information/leflunomide-teva-epar-product-information_no.pdf)

polski (PL) (1.52 MB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/pl/documents/product-information/leflunomide-teva-epar-product-information_pl.pdf)

português (PT) (872.02 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/pt/documents/product-information/leflunomide-teva-epar-product-information_pt.pdf)

română (RO) (1.05 MB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/ro/documents/product-information/leflunomide-teva-epar-product-information_ro.pdf)

slovenčina (SK) (1.49 MB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/sk/documents/product-information/leflunomide-teva-epar-product-information_sk.pdf)

slovenščina (SL) (1.29 MB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/sl/documents/product-information/leflunomide-teva-epar-product-information_sl.pdf)

Suomi (FI) (893.67 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/fi/documents/product-information/leflunomide-teva-epar-product-information_fi.pdf)

svenska (SV) (885.63 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/sv/documents/product-information/leflunomide-teva-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0011 15/01/2014

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Leflunomide Teva : EPAR - All Authorised presentations

English (EN) (169.19 KB - PDF)

**First published:** 21/03/2011

**Last updated:** 18/03/2014

[View](/en/documents/all-authorised-presentations/leflunomide-teva-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-664)

български (BG) (200.8 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/bg/documents/all-authorised-presentations/leflunomide-teva-epar-all-authorised-presentations_bg.pdf)

español (ES) (159.65 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/es/documents/all-authorised-presentations/leflunomide-teva-epar-all-authorised-presentations_es.pdf)

čeština (CS) (191.43 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/cs/documents/all-authorised-presentations/leflunomide-teva-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (164.47 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/da/documents/all-authorised-presentations/leflunomide-teva-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (159.04 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/de/documents/all-authorised-presentations/leflunomide-teva-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (159.01 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/et/documents/all-authorised-presentations/leflunomide-teva-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (207.69 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/el/documents/all-authorised-presentations/leflunomide-teva-epar-all-authorised-presentations_el.pdf)

français (FR) (156.36 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/fr/documents/all-authorised-presentations/leflunomide-teva-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (176.42 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/hr/documents/all-authorised-presentations/leflunomide-teva-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (169.87 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/is/documents/all-authorised-presentations/leflunomide-teva-epar-all-authorised-presentations_is.pdf)

italiano (IT) (159.13 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/it/documents/all-authorised-presentations/leflunomide-teva-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (201.01 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/lv/documents/all-authorised-presentations/leflunomide-teva-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (192.59 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/lt/documents/all-authorised-presentations/leflunomide-teva-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (197.92 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/hu/documents/all-authorised-presentations/leflunomide-teva-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (207.54 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/mt/documents/all-authorised-presentations/leflunomide-teva-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (158.08 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/nl/documents/all-authorised-presentations/leflunomide-teva-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (159.25 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/no/documents/all-authorised-presentations/leflunomide-teva-epar-all-authorised-presentations_no.pdf)

polski (PL) (177.78 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/pl/documents/all-authorised-presentations/leflunomide-teva-epar-all-authorised-presentations_pl.pdf)

português (PT) (159.95 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/pt/documents/all-authorised-presentations/leflunomide-teva-epar-all-authorised-presentations_pt.pdf)

română (RO) (182.7 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/ro/documents/all-authorised-presentations/leflunomide-teva-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (206.16 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/sk/documents/all-authorised-presentations/leflunomide-teva-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (167 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/sl/documents/all-authorised-presentations/leflunomide-teva-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (162.38 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/fi/documents/all-authorised-presentations/leflunomide-teva-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (159.1 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/sv/documents/all-authorised-presentations/leflunomide-teva-epar-all-authorised-presentations_sv.pdf)

Leflunomide Teva : EPAR - Conditions imposed on member states for safe and effective use - Annex IV

English (EN) (477.32 KB - PDF)

**First published:** 21/03/2011

**Last updated:** 18/03/2014

[View](/en/documents/conditions-member-states/leflunomide-teva-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_en.pdf)

[Other languages (23)](#file-language-dropdown-107)

български (BG) (245.7 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/bg/documents/conditions-member-states/leflunomide-teva-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_bg.pdf)

español (ES) (151.4 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/es/documents/conditions-member-states/leflunomide-teva-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_es.pdf)

čeština (CS) (287.59 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/cs/documents/conditions-member-states/leflunomide-teva-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_cs.pdf)

dansk (DA) (478.13 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/da/documents/conditions-member-states/leflunomide-teva-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_da.pdf)

Deutsch (DE) (151.32 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/de/documents/conditions-member-states/leflunomide-teva-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_de.pdf)

eesti keel (ET) (150.94 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/et/documents/conditions-member-states/leflunomide-teva-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_et.pdf)

ελληνικά (EL) (240.55 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/el/documents/conditions-member-states/leflunomide-teva-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_el.pdf)

français (FR) (150.44 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/fr/documents/conditions-member-states/leflunomide-teva-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_fr.pdf)

íslenska (IS) (150.99 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/is/documents/conditions-member-states/leflunomide-teva-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_is.pdf)

italiano (IT) (151.42 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/it/documents/conditions-member-states/leflunomide-teva-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_it.pdf)

latviešu valoda (LV) (234.3 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/lv/documents/conditions-member-states/leflunomide-teva-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_lv.pdf)

lietuvių kalba (LT) (217.42 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/lt/documents/conditions-member-states/leflunomide-teva-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_lt.pdf)

magyar (HU) (227.66 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/hu/documents/conditions-member-states/leflunomide-teva-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_hu.pdf)

Malti (MT) (230.35 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/mt/documents/conditions-member-states/leflunomide-teva-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_mt.pdf)

Nederlands (NL) (151.11 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/nl/documents/conditions-member-states/leflunomide-teva-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_nl.pdf)

norsk (NO) (150.92 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/no/documents/conditions-member-states/leflunomide-teva-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_no.pdf)

polski (PL) (233.48 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/pl/documents/conditions-member-states/leflunomide-teva-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_pl.pdf)

português (PT) (151.96 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/pt/documents/conditions-member-states/leflunomide-teva-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_pt.pdf)

română (RO) (220.84 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/ro/documents/conditions-member-states/leflunomide-teva-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_ro.pdf)

slovenčina (SK) (229.89 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/sk/documents/conditions-member-states/leflunomide-teva-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_sk.pdf)

slovenščina (SL) (233.43 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/sl/documents/conditions-member-states/leflunomide-teva-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_sl.pdf)

Suomi (FI) (152.05 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/fi/documents/conditions-member-states/leflunomide-teva-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_fi.pdf)

svenska (SV) (150.55 KB - PDF)

**First published:**

21/03/2011

**Last updated:**

18/03/2014

[View](/sv/documents/conditions-member-states/leflunomide-teva-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_sv.pdf)

## Product details

Name of medicine Leflunomide Teva Active substance leflunomide International non-proprietary name (INN) or common name leflunomide Therapeutic area (MeSH) Arthritis, Rheumatoid Anatomical therapeutic chemical (ATC) code L04AA13

### Pharmacotherapeutic group

Immunosuppressants

### Therapeutic indication

Leflunomide is indicated for the treatment of adult patients with active rheumatoid arthritis as a 'disease-modifying antirheumatic drug' (DMARD).

Recent or concurrent treatment with hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) may result in an increased risk of serious adverse reactions; therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.

Moreover, switching from leflunomide to another DMARD without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.

## Authorisation details

EMA product number EMEA/H/C/002356

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Teva Pharma B.V.

Computerweg 10

Marketing authorisation issued 10/03/2011 Lapse of marketing authorisation 10/03/2014 Revision 6

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Leflunomide Teva : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (240.41 KB - PDF)

**First published:** 20/09/2011

**Last updated:** 18/03/2014

[View](/en/documents/procedural-steps-after/leflunomide-teva-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Leflunomide Teva : EPAR - Public assessment report

Adopted

Reference Number: EMA/79144/2011

English (EN) (451.78 KB - PDF)

**First published:** 21/03/2011

**Last updated:** 18/03/2014

[View](/en/documents/assessment-report/leflunomide-teva-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Leflunomide Teva

Adopted

Reference Number: EMA/CHMP/605159/2010

English (EN) (182.64 KB - PDF)

**First published:** 17/12/2010

**Last updated:** 18/03/2014

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-leflunomide-teva_en.pdf)

#### More information on Leflunomide Teva

Public statement on Leflunomide Teva: Cessation of validity of the marketing authorisation in the European Union

Reference Number: EMA/143186/2014

English (EN) (68.03 KB - PDF)

**First published:** 18/03/2014

**Last updated:** 18/03/2014

[View](/en/documents/public-statement/public-statement-leflunomide-teva-cessation-validity-marketing-authorisation-european-union_en.pdf)

**This page was last updated on** 18/03/2014

## Share this page

[Back to top](#main-content)